The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Author(s): Jie Li, Jingyu Zhu, Biyin Cao, Xinliang Mao

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.

Keywords: Mammalian target of rapamycin (mTOR), mTOR complex 1, mTOR complex 2, multiple myeloma, drug discovery.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 13 January, 2014
Page: [125 - 135]
Pages: 11
DOI: 10.2174/13816128113199990638
Price: $65

Article Metrics

PDF: 57